Hyaluronic Acid (HA) and PRP Injections

2026 Guidance: Two Bodies, Two Tones

Two authoritative documents landed in 2026 and they do not fully agree, which is worth understanding before spending cash on injections:

• AAOS ankle osteoarthritis guideline (2026): strong recommendation against HA alone; PRP not routinely suggested (moderate), on evidence that saline matched or beat PRP through 12 months; no reliable evidence for stem cell therapy; corticosteroid an option for short-term relief; skilled physical therapy and weight reduction suggested [228]
• International Consensus Meetings on Cartilage Repair of the Ankle (July 2026): 75 experts, 29 statements. More permissive — PRP, bone marrow aspirate, and HA are “appropriate in select patients with persistent symptoms” — but with a hard finding attached: no superiority among formulations, preparation methods, or injection strategies, and only limited evidence of clinical benefit when used as a surgical adjunct [216]
• How to reconcile them: AAOS addresses diffuse ankle osteoarthritis; a focal postoperative OLT is not the same condition, which is why the OLT-focused panel is more permissive. Both agree on the practical point — no product has been shown to beat another, so paying a premium for a specific formulation is not evidence-supported
• A July 2026 narrative review adds that PRP's most consistent foot-and-ankle evidence is in plantar fasciitis and OLT, with mixed results in ankle osteoarthritis attributed to preparation heterogeneity [224]

The Strongest Trial Yet: Cross-Linked HA vs Saline in the Knee (April 2026)

→ 276 people, three groups, nobody knew which they got: two premium hyaluronic acid products, or plain salt water. All three groups got better. None got better than the others.

A double-blind, randomized, placebo-controlled Therapeutic Level I trial gave a single intra-articular injection to 276 knee osteoarthritis patients in three arms of 92 — ultra-high molecular weight cross-linked HA, high molecular weight cross-linked HA (hylan G-F 20 / Synvisc), or saline — and followed them 24 weeks [236]:

• No difference on any outcome. VAS pain at rest p=0.92, on motion p=0.99; modified WOMAC, SF-36, Lequesne, timed-up-and-go, and knee flexion all non-significant. Rescue corticosteroid use 17% / 21% / 25%, p=0.98
• All three arms improved significantly over 24 weeks (p<0.0001), saline included. This is the important mechanism to understand: a large placebo and regression-to-the-mean effect is exactly how an ineffective injection reliably feels like it worked
• The HA products were donated by the manufacturer of one of them — an industry-supplied negative result, which strengthens the finding

The limit that matters: this is a knee trial in degenerative osteoarthritis, not a focal postoperative talar lesion, and it should not be treated as though it settles the ankle question. It does not. But a January 2026 Foot & Ankle Specialist meta-analysis concluded the ankle evidence for intra-articular HA is limited, and taken with the AAOS guideline and the consensus statement above, the direction of travel is consistent.

Correction: randomized HA-versus-saline trials in the ankle do exist

→ This page previously said no such trial had ever been run in an ankle. That was wrong, and the truth is more useful: two have been run, they injected the ankle joint directly, and they disagree with each other.

An earlier version of this section stated that no Level I HA-versus-saline trial existed in the ankle at all. That claim was incorrect and is withdrawn. At least two randomized, double-blind, saline-controlled trials have injected the tibiotalar joint directly:

• Cohen 2008 — the abstract reports a positive result, but the AAOS systematic review reads it the opposite way. See the correction immediately below. Thirty patients with radiographically documented ankle osteoarthritis received five weekly injections of either sodium hyaluronate (Hyalgan) or phosphate-buffered saline. The published abstract reports that at three months the HA group improved significantly more on the Ankle Osteoarthritis Scale (−17.4 ± 5.0 mm versus −5.1 ± 4.0 mm, p=0.041), with low adverse events in both arms [244]
• DeGroot 2012 — negative, and larger. Sixty-four patients were randomized to a single injection of low-molecular-weight, non-cross-linked HA or normal saline. AOFAS score improved by 4.9 points at both six and twelve weeks in the HA arm; the saline arm worsened slightly at six weeks and then improved by 5.4 points at twelve. Both groups improved substantially by twelve weeks and the between-group differences were not significant. The authors concluded HA was not demonstrably superior to saline [245]

Second correction, July 29, 2026: there are three trials, not two — and none of them favours HA

→ The 50-page AAOS guideline was read in full for the first time this week, rather than relying on its press release. It disagrees with what this page said about the Cohen trial one week ago, it names a third trial this page did not have, and it points to a different question worth asking.

The July 28 entry above framed the ankle evidence as “one small positive trial against one larger negative one.” The AAOS workgroup's own systematic review states something different. Quoted verbatim from the guideline document:

“Three high-quality RCTs evaluated intraarticular (IA) hyaluronic acid (HA) versus saline control with 1.5-6 month follow-up. Cohen 2008 found saline superior to HA across multiple outcomes at 1.5, 3, and 6 months (AOS Total, WOMAC Total, Pain scores). DeGroot 2012 found no differences between HA and saline. Kubo 2022 showed diclofenac etalhyaluronate (DF-HA) reduced adverse events but no improvement in patient-reported outcomes. Meta-analysis confirmed no benefit of HA over saline.”

Both readings can be literally true of different analyses. Cohen's own abstract reports a favourable HA result on one instrument at one timepoint; the AAOS reviewers re-extracted outcomes across three timepoints and three instruments and concluded saline came out ahead. Where a trial abstract and a formal systematic review with risk-of-bias assessment disagree, the systematic review is the better guide, and this page now defers to it.

The consequence for the framing is real. The ankle HA literature is not a split decision. It is three high-quality randomized trials, none of which favours HA, plus a meta-analysis finding no benefit over saline — which is why the recommendation against it is rated Strong at a High quality of evidence. That is the guideline's only strong recommendation, in a document that makes just two.

The question this page has never asked: HA with a corticosteroid

The same recommendation contains a carve-out that has been overlooked here: HA alone is not recommended, “however, there may be a benefit for short term improvement in pain and function when combined with corticosteroid.” Two high-quality randomized trials sit behind that clause, and neither was previously on this page:

• Gomes 2023 — HA plus intra-articular corticosteroid versus corticosteroid alone in subtalar post-traumatic osteoarthritis. Combination was superior for VAS pain at one month, and for both AOFAS Total and VAS pain at three months, with trends persisting at six [262]
• Woo 2025 — dual injection of corticosteroid plus HA versus a single corticosteroid injection for ankle osteoarthritis. Combination was superior on Ankle Osteoarthritis Scale Total at 1.5 and 3 months [263]

The limit is decisive and the guideline states it plainly: “neither study compared combination therapy to placebo, so absolute efficacy cannot be determined.” So this is not evidence that combination injection works — only that it outperforms corticosteroid alone over roughly six weeks to three months. Both trials are also short, and one is the subtalar rather than the tibiotalar joint.

Why it still matters here. What is currently being paid for out of pocket is HA alone — precisely the intervention carrying a strong recommendation against it at high quality of evidence. The guideline's only carve-out is for HA combined with a corticosteroid. That is a specific, concrete question to raise with Dr. Salk before committing to another Supartz series, and it is a genuinely different question from “should I repeat the same thing.”

The guideline's own cost language bears directly on a cash-pay decision: HA “costs $500-2000+ per injection series,” and “given lack of efficacy versus placebo, routine use represents poor resource utilization.” It also anticipates “false patient expectations” and notes that “stakeholder resistance [is] expected given widespread HA marketing.” Two adjacent recommendations were read at the same time: intra-articular PRP is “not routinely suggested” (moderate quality, moderate strength against), and on stem cells the workgroup's position is that “there is no reliable evidence regarding intra-articular stem cell therapy” for ankle osteoarthritis.

The scope caveat, which is important and cuts the other way. This guideline addresses ankle osteoarthritis, not focal osteochondral lesions of the talus. It is not a direct verdict on HA for an isolated Hepple V lesion, and the trials enrolled diffuse degenerative disease rather than a focal postoperative defect. What it does establish is that the strongest ankle-specific evidence available points against the thing currently being paid for — and that the individual measured response is now the only ankle-specific evidence that could point the other way. That makes the pre-set August check-in more useful, not less, and it makes a general impression of improvement worth very little against saline arms that improved substantially in every one of these trials.

HA Systematic Review Evidence (RCTs)

→ HA is a gel-like lubricant naturally in joints. PRP uses your own blood's healing factors. Neither creates new cartilage, but they may reduce inflammation and pain.

A systematic review of 3 randomized controlled trials (132 patients) found HA injection as an adjunct to microfracture provides clinically important improvements [15]:

→ RCT = Randomized Controlled Trial (gold-standard study design); adjunct = added alongside another treatment

• AOFAS scores: Greater improvement vs microfracture alone (moderate effect size, p=0.02)
  → AOFAS = American Orthopaedic Foot & Ankle Society score (0-100); measures pain, function, alignment
• VAS-pain scores: Significantly greater improvement (very large effect size, p<0.001)
• After failed surgery: HA injections significantly improved clinical scores

PRP Meta-Analysis (December 2024)

A 2024 meta-analysis from the Journal of Orthopaedic Surgery and Research (5 RCTs) found [67]:

→ SMD = Standardized Mean Difference; negative value = less pain (good); OA = osteoarthritis

• Subgroup analysis: More significant effect in patients with talar cartilage injuries specifically
• PRP treatment effect remained effective in long-term follow-up
• Greater advantage for cartilage injuries of the talus vs general ankle OA

PRP Complications (2025 Systematic Review)

A 2025 systematic review from Arthroscopy Journal found important safety data [68]:

• 674 patients receiving PRP vs 749 receiving alternatives
• Complication rate: 41.1% (PRP) vs 33.7% (comparison group)
• Most common: treatment-site pain (15.1% vs 10.2%, p<0.01)
• Number needed to harm: 13 patients
  → NNH = on average, for every 13 patients treated with PRP, 1 extra complication occurs vs alternative

Network Meta-Analysis of Adjunctive Therapies (2024)

A network meta-analysis of 6 RCTs (295 patients) compared adjuncts to microfracture [69]:

→ Network meta-analysis = combines multiple studies to compare treatments that may not have been directly compared

• Compared: PRP, HA, collagen scaffold, pulsed electromagnetic fields (PEMF)
  → PEMF = therapy using magnetic waves to stimulate healing
• PRP + MF showed superior final VAS and AOFAS scores vs MF only (p<0.01)
  → MF = microfracture

FDA Note

HA was FDA approved in 1997 for knee osteoarthritis only. FDA has not approved intra-articular HA for ankle joints, though it is commonly used off-label [17]. A 2024 CADTH rapid review confirmed limited evidence for ankle applications [70].

→ Intra-articular = injected into the joint; off-label = approved for another use but legally prescribed by doctors for this one

Added August 5, 2026 — the international consensus was asked directly about HA, and its answer left HA out

→ This is the missing paper from a series this site otherwise holds in full, and it is the one paper in that series about the branch of treatment he is actually in right now.

The 2017 International Consensus Meeting on Cartilage Repair of the Ankle produced eleven working-group papers. This site held ten of them. The eleventh — the only one on conservative and biological management — was missing, and it was found this week by checking the series for completeness rather than by any date-windowed search [360]. 75 experts, 25 countries, Delphi method, 12 statements.

One statement matters more than the rest here, and it matters because of what it omits. The working group put the question in deliberately broad terms — “Can the injection of a biological product (eg, cBMA, HA, PRP, adipose, etc) be considered as a conservative management strategy for a cartilage lesion of the ankle? If so, when?” HA is named in the question. The agreed answer:

“The injection of a biological product in the form of concentrated bone marrow aspirate or platelet-rich plasma can be considered as a conservative management strategy for a cartilage lesion of the ankle if there is no improvement in symptoms after 4-6 weeks.”

Asked about HA, cBMA, PRP and adipose, the panel endorsed two of them and quietly dropped HA from its own answer. That is not a statement against HA — it is an omission, and it should be read as one — but it is an omission by the largest expert panel ever assembled on this exact question, and it converges with everything else on this page.

Read it with its weaknesses, which are real. This was the weakest consensus in the paper: 61% agree / 39% disagree, which is bare “consensus” on the paper's own scale (51–74%) rather than the strong consensus ten of the twelve statements achieved. Grade of evidence B1. And it is 2017 work published in 2018, so it predates every trial in the corrections above. It does not settle anything on its own; it is one more independent panel declining to endorse the injection he has been paying cash for.

→ Practical read: this does not mean stop — the May 18 Supartz gave real relief and that is his own evidence. It means that if the next conversation is about what to try before surgery, cBMA and PRP are the two the consensus actually named, and it is reasonable to ask why the plan has been HA instead. It also matters for cost: Anthem excludes HA class-wide, so he is paying cash for the one option the panel omitted.